Intentionally Curated Nexus of Companies
Our strategic focus aims at fostering cross-venture support while designing streamlined drug development paths to achieve accelerated de-risking, value creation, and diversification, underscoring our commitment to rapidly advance innovative treatments for patients in need
Landmark BioVentures operates a highly efficient, accelerated lean business model, focusing on groundbreaking programs targeting critical intersections of neoplasm, uncontrolled inflammation, neovascularization, and fibrosis
Duhn Therapeutics
Lipid Based Immunotherapies
Duhn Therapeutics is a clinical-stage company advancing lipid-based cancer immunotherapies with the mission is to bring new solutions to cancer patients by reshaping the immunological profile of their tumors
Carla Biotherapeutics
Adoptive Cell Therapies
CARLA Biotherapeutics develops cell-based immunotherapies to treat a broad range of diseases with an initial focus in hematological malignacies and solid tumors
Roca Therapeutics
Medicines Against Severe Retinal Disorders
Roca Therapeutics is a VC-backed biotechnology start-up dedicated to the development of first-in-class small molecules following a systems level-based approach, addressing exacerbated angiogenesis, oxidative stress, chronic non-resolved macrophage driven inflammation
Kekkan Biologics
Novel Biologics Against Severe Neovascular and Fibrotic Disorders
Kekkan Biologics is a platform company developing first-in-class biologics against severe neovascular and fibrotic disorders. Kekkan focuses on a novel target, LVRF, involved in lymphatic and vascular angiogenesis, and involved in drug resistance
Elikya Therapeutics
Next-Gen ADC Design
Elikya Therapeutics is focused on the development of first-in-class toxic payloads for Antibody Drug Conjugates and intra-tumoral therapies with differentiated mechanisms of action against cancer cells and tumoral micro-environment
SPIMA Therapeutics
Unlocking New Paths with Smart Peptides
SPIMA Therapeutics develops smart peptide-based immunotherapies to address undruggable targets.
The company is aiming to bring innovative medicines to patients for diseases with challenging immunological avenues
Massalia Therapeutics
Targeting Novel Paths to Halt Fibrotic Diseases and Cancers
Massalia Therapeutics is developing mono- and bi-specific antibodies against novel targets involved in aggressive fibrotic conditions and resistant cancers